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1. Introduction  
Although it is noted throughout the literature that adverse effects occur, one review of 
safety reporting determined clinical trials only report adverse effects between 29% 
(laboratory adverse effects) and 39% (clinical adverse effects) (Ioannidis, et al, 2001). It is 
important to keep these numbers in mind when looking at the number of drug-induced 
hypoglycemia cases. Seltzer’s review of the literature from 1940 to 1989 reveals 1418 
documented cases of drug-induced hypoglycemia. Based on estimates of the lack of adverse 
effect reporting, it is unlikely that these cases were the only incidents of drug-induced 
hypoglycemia that occurred during this time (Seltzer, 1989).  
It is also reasonable to look at estimates of adverse drug effects (ADEs) in hospitalized 
patients. Such estimates indicate ADEs may account for between 3 and 5% of all hospital 
admissions (Pandit et al, 1993). In a 2006 study it was determined approximately 22% of 
admissions attributed to ADEs were due to hypoglycemia at a university hospital versus 23% 
at a community hospital (Kilbridge et al, 2006). These admissions were related to an overall 
admission rate attributed to ADEs of 4.4% at the university hospital and 6.2% at a community 
hospital (Kilbridge et al, 2006). In addition there are estimates that as many as 30% of 
hospitalized patients experience an ADE while in the hospital (Pandit et al, 1993). Estimates of 
3 – 4.5 billion dollars, which is now outdated, just begin to attribute a cost to treating ADEs. 
However, the cost is probably grossly underestimated since the actual number of ADEs 
reported is underestimated (Pandit et al, 1993). Not only is the cost of managing an ADEs a 
significant issue but the risk of mortality must be considered as well. Mortality has been 
estimated to occur in as many as 140,000 patients each year (Pandit et al, 1993). One study 
looking at death due to drug-induced hypoglycemia determined a 1.3% mortality rate 
(Juurlink et al, 2003).  
The incidence and impact of drug-induced hypoglycemia should be contrasted with the 
incidence and impact of hypoglycemia in patients with diabetes mellitus (DM) – type 1 or 
type 2. For patients with type 1 DM, it is estimated that hypoglycemia, by the numbers 
(blood glucose less than 50 – 60 mg/dL), occurs 1 in 10 times when patients check their 
blood glucose (Cryer et al, 2003). While the number of asymptomatic hypoglycemia 
episodes is undocumented, it is estimated that patients with type 1 DM experience “an 
average of 2 symptomatic hypoglycemic episodes per week.and an episode of severe, at 
least temporarily disabling hypoglycaemia once a year” (Cryer et al, 2003). The incidence of 
hypoglycemia in patients with type 2 DM is more challenging. When comparing the 
incidence of severe hypoglycemia in patients with type 1 DM versus patients with type 2 
DM being treated with insulin, estimates are anywhere from 10% to equal incidence of 
hypoglycemia (Cryer et al, 2003). Other studies that have tried to quantify the incidence of 
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hypoglycemia in type 2 patients have varied from an overall incidence of 20% in patients 
taking oral agents to 0.5% episodes of severe hypoglycemia in patients using insulin 
(Jennings AM et al, 1989 & Miller CD et al, 2001).  Unfortunately, as with drug-induced 
hypoglycemia, hypoglycemia may result in death. One estimate of the rate of death from 
hypoglycemia is 2 to 4% of patients with type 1 DM, but, as with the incidence of 
hypoglycemia, there is not a reliable estimate of death attributed to hypoglycemia in 
patients with type 2 DM (Cryer et al, 2003). However, a 1999 review of cases of 
hypoglycemic coma provides some perspective on potential morbidity and mortality. In this 
study, out of 102 reported cases, 5 patients died. (Ben-Ami et al, 1999).  
These statistics emphasize the importance of recognizing and treating hypoglycemia as well 
as ADEs when they occur. The numbers also serve as a reminder to all healthcare providers 
of their responsibility in the prevention of ADEs, especially drug-induced ADEs. However, 
in order to prevent ADEs, one must know what patients are at risk for development of an 
ADE. The risk for drug-induced hypoglycemia, the mechanism of potentially causative 
agents as well as management and prevention are discussed below in effort to make 
healthcare providers aware of this potential ADE and how to avoid it. 
2. Definition of hypoglycemia 
Before determining if a patient is experiencing drug-induced hypoglycemia, the definition of 
hypoglycemia should be established. Since all patients respond to blood glucose 
concentrations differently, it is challenging to establish a blood glucose at which every patient 
will experience symptoms. However, it is widely accepted that most patients will begin to 
experience symptoms when their blood glucose level is less than 3.3 mmol/l (60 mg/dL). The 
symptoms patients commonly experience are listed in Table 1 below and can be manifestations 
of the response by the autonomic nervous system as well as the brain’s response to being 
deprived of glucose (Cryer et al, 2003, White, 2007). Physiologic responses with escalating 
hypoglycemia are shown in Table 2. Severe episodes of hypoglycemia may be characterized by 
loss of consciousness and/or seizures and, in instances of sustained hypoglycemia, may result 
in brain damage or death (Cryer et al, 2003). The blood glucose level at which a patient 
experiences symptoms of hypoglycemia can be influenced by other factors such as: the 
frequency of hypoglycemic episodes, which may result in hypoglycemic unawareness; 
frequent hyperglycemia episodes, and increased caffeine intake (Cryer et al, 1999).  
 
Neurogenic Symptoms of 
Hypoglycemia 
Neuroglycopenic Symptoms of  
Hypoglycemia 
Physical Signs of 
Hypoglycemia 
Anxiety/arousal Blurry vision Increased systolic 
blood pressure 
Hunger Changes in behavior – irritability is often noted Pallor
Shaky/trembling Confusion/difficulty thinking
Difficulty speaking
Sweating 
Parethesias Dizziness
Sweating  Emotional lability
Fatigue 
Loss of consciousness 
seizures 
Warmth 
Weakness 
Tachycardia 
Adapted from Cryer et al, 2003 and White, 2007  
Table 1. Common symptoms of hypoglycemia 
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Blood glucose level Classification Physiologic response 
70 mg/dl (3.9 mmol/l) Hypoglycemia  Glucagon release 
 Epinephrine release 
 Growth hormone release 
 Cortisol release 
54 mg/dl (3 mmol/l) Symptomatic hypoglycemia  Autonomic symptoms 
36 mg/dl (2 mmol/l) Hypoglycemia affecting 
brain function 
(neuroglucopenia) 
 Cognitive decline 
18 mg/dl (1 mmol/l) Severe neuroglucopenia  Coma 
 Seizures 
Adapted from White, 2007  
Table 2. Physiologic response based on blood glucose level 
It is important to note that monitoring blood glucose levels is the best way to monitor 
hypoglycemia since hemoglobin A1C (A1C) does not adequately depict hypoglycemia given 
that A1C provides a measure of average control of blood glucose over the past 2 to 3 months 
(American Diabetes Association, 2011).  
In one technical review of hypoglycemia in patients with diabetes, it was noted that 
hypoglycemia resulted in “physical morbidity” as evidenced in the physical symptoms and 
even neurologic impairment patients may experience as well as “psychological morbidity” 
which were differences in moods and outlook as a result of experiencing hypoglycemia 
(Cryer PE et al, 2003). Specific manifestations of physical and psychological morbidity are 
detailed in Table 3. When thinking of these symptoms of hypoglycemia, it should be 
recognized that they can make patients feel uncomfortable physically as well as socially 
since experiencing these symptoms may result in patients receiving unwanted attention. It is 
important to consider that hypoglycemia affects patients both physically, psychologically, 
and can have a significant impact on a patient’s overall sense of well-being. Although the 
same evidence does not exist for patients that experience drug-induced hypoglycemia, it 
could be argued that the toll is equally as hard on these individuals and therefore, 
emphasizes the importance of avoiding drug-induced hypoglycemia.   
   
Examples of Physical Morbidity 
Associated with Hypoglycemia 
Examples of Psychological Morbidity 
Associated with Hypoglycemia 
Physical symptoms – anxiety, hunger, 
palpitations, sweating, hunger 
Fear of experiencing hypoglycemia 
Neurologic impairment – changes in 
behavior, decline in cognitive function, 
seizures, coma  
Guilt related to being fearful of 
experiencing hypoglycaemia 
Anxiet 
overall happiness  
Adapted from Cryer PE et al, 2003 
Table 3. Physical and psychological morbidity associated with hypoglycemia. 
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3. Risk factors 
Table 4 lists patient characteristics that may increase the risk of drug-induced hypoglycemia. 
Specific pharmacokinetic and pharmacodynamic drug parameters may affect the level of 
risk associated with the described patient characteristics.   
 
Risk Factors Mechanism 
Advancing age 
Decreased symptoms/decreased awareness, 
decreased counterregulatory response to low 
blood glucose 
Renal insufficiency Decreased insulin clearance 
Hepatic insufficiency Decreased gluconeogenesis 
Decreased food intake (skipping meals) Insufficient glucose intake 
Excessive alcohol intake Decreased gluconeogenesis 
Polypharmacy 
Increased risk of drug interactions resulting in 
hypoglycemia 
Table 4. Risk factors for drug-induced hypoglycemia 
It should be noted that the risk factors associated with drug-induced hypoglycemia are similar 
to the risk factors associated with the development of hypoglycemia in patients with DM. In 
particular it is known that advanced age, alcohol intake, and polypharmacy are all risk factors 
for hypoglycemia in patients with type 1 diabetes (Zammitt et al, 2005). As noted above, these 
are risk factors that may also place patients at risk for drug-induced hypoglycemia. In addition 
to the risk factors discussed above, risk factors that place patients with type 1 diabetes at risk 
for hypoglycemia are:  caffeine intake; variations in sleep; and physical activity, in particular 
exercise, in relation to meals and medications (Zammitt et al, 2005). However, it is unknown 
how these factors affect the risk of hypoglycemia in patients with type 2 diabetes (Zammitt et 
al, 2005). It is known that patients with type 2 diabetes who have been taking in insulin for 
more than 10 years are increased risk for experiencing hypoglycemia (Zammitt et al, 2005). 
Obviously, the greatest concern for the development of drug-induced hypoglycemia becomes 
when patients have pre-exsiting diabetes and then are placed on a medication that has the 
potential to cause hypoglycemia.  
4. Glucose regulation 
Changes in serum glucose levels are a result of the following process:  glucose absorption from 
the gastroinstestinal tract, release of stored glucose through hepatic glycogenolysis, and 
creation of glucose from non-glucose sources through hepatic gluconeogenesis. 
Glycogenolysis releases glucose through breakdown of glycogen, the stored form of glucose, 
and glycogenolysis creates glucose from amino acid and lactate. All three processes affect 
glucose levels based on proximity to meals. The rate of rise of serum glucose during and after 
meals is predominantly a result of the rate of gastric emptying. Rate of gastric emptying 
determines amount of glucose absorbed in gastrointestinal tract. During periods of fasting, 
glucose levels are regulated by glycogenolysis and gluconeogenesis. Glycogenolysis impacts 
serum glucose levels in the first 8 to 12 hours of fasting, while gluconeogenesis contributes 
more to glucose levels after longer periods of fasting (Aronoff et al, 2004).  
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The processes above are all regulated by glucoregulatory hormones. The hormones, their 
site of origin, and specific gluco-regulatory actions are listed in table 5. In addition to those 
listed, blood glucose levels are affected by epinephrine, cortisol, and growth hormones 
(Aronoff et al, 2004).  
 
Hormone Site of origin/production Action 
Insulin Beta (ǃ)-cells of the pancreas Induces uptake of glucose by cells 
Inhibits glucagon secretion post-
prandially 
Enhances protein and fat synthesis 
Stimulates glycogenesis in the liver 
Glucagon Alpha (ǂ)-cells of the 
pancreas 
Stimulates hepatic glycogenolysis, 
hepatic gluconeogenesis, and 
hepatic ketogenesis 
Amylin Β-cells of the pancreas Slows gastric emptying 
Inhibits glucagon secretion post-
prandially 
Decreases food intake  
Glucagon-like 
peptide 1 (GLP-1) 
L-cells of the intestine Slows gastric emptying 
Stimulates glucose-dependent 
(prandial) insulin secretion 
Inhibits glucagon secretion post-
prandially 
Decreases food intake 
Glucose-
dependent 
insulinotropic 
peptide (GIP), 
L-cells of the intestine Stimulates glucose-dependent 
(prandial) insulin secretion 
Inhibits glucagon secretion post-
prandially 
Table 5. Gluco-regulatory hormones 
Insulin and glucagon play large roles in the overall regulation of blood glucose (Figure 1). 
Increases in serum blood glucose stimulate insulin release from the pancreas. The amount of 
insulin released is dependent on the level of blood glucose. Insulin is not released until 
blood glucose levels reach 3.3 mmol/l (59.4 mg/dl). Insulin acts to both decrease existing 
glucose in the blood and to decrease production of further glucose. Insulin binds to 
receptors on fat, muscle, and liver cells to stimulate glucose uptake. Additional serum 
glucose is converted to glycogen, the storage form of glucose, through hepatic glycogenesis. 
Insulin decreases production of glucose from gluconeogenesis and glycogenolysis by 
inhibiting glucagon release from the pancreas. The combination of these actions results in a 
decrease in serum blood glucose. Glucagon serves as the hormone that balances the glucose 
lowering effects of insulin. Glucagon controls fasting levels by stimulating gluconeogenesis 
and glycogenolysis in the liver. Stimulation of these mechanisms results in release of 
glucose, increasing serum blood glucose levels. Release of glucagon from the pancreas 
occurs when serum glucose levels fall below approximately 5 mmol/l (90 mg/dl) (Aronoff 
et al, 2004).   
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Fig. 1. Glucose regulation (Dugi K, 2009) 
5. Causative agents  
5.1 There are a number of agents implicated in causing hypoglycemia; however, the level of 
evidence available varies significantly amongst agents. The most highly documented drug-
induced hypoglycemia occurs with medications used to treat hyperglycemia. The specific 
agents and classes are included in table 6 below.  
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Anti-diabetic agents  
Exenatide 
Insulin 
Pramlintide 
Secratagogues (non-sulfonylurea) 
Sitagliptin 
Sulfonylureas 
Table 6. Anti-diabetic agents with greatest evidence of causing hypoglycaemia  
Of potentially greater concern are the agents which are used for indications other than 
hyperglycemia because the hypoglycemic episodes are often less predictable and/or 
unexpected. These agents often have very little or no quality evidence to document the 
frequency and severity of their hypoglycemic effects. This is illustrated in the systematic 
review of literature through 2007 conducted by The Hypoglycemia Task Force of The 
Endocrine Society which identified hypoglycemia associated with 164 different medications 
(Murad et al, 2009). This study found that no individual or class of drugs has high quality 
evidence supporting its impact on glucose levels, though drugs used to treat hyperglycemia 
were not included. Table 7 provides a list of the most commonly cited agents in the 
literature and their level of evidence. Level of evidence was defined by use of the GRADE 
approach to literature evaluation. Available evidence was evaluated for quality of study 
design, strength of association of the medication to the reported adverse effects, and 
quantity of evidence available (Murad et al, 2009). 
 
Moderate Quality Evidence
Agent/Class Mechanism of hypoglycemia
Fluoroquinolones (gatifloxacin) Unclear
May increase insulin secretion from pancreas 
Indomethacin Increase insulin secretion from pancreas, decrease in 
insulin clearance, decrease in gluconeogenesis, and 
increase in glucose uptake in periphery
Pentamadine Increased insulin secretion from pancreas through cell 
damage
Quinine Increased insulin secretion from pancreas
Poor Quality Evidence
Agent/Class Mechanism of hypoglycemia
Angiotensin Converting 
Enzyme Inhibitors (ACEIs)
Increase insulin sensitivity
Beta blockers Mask signs/symptoms of hypoglycemia, increase in 
glucose uptake in the periphery
Ethanol Decrease in gluconeogenesis in the liver
Lithium Unclear
Propoxyphene Unclear
Sulfamethoxazole Increase insulin secretion from pancreas
Table 7. Strength of evidence of drug-induced hypoglycemia and proposed mechanisms 
(Murad, et al, 2009). 
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Drug-induced hypoglycemia may be a result of direct changes to glucose homeostasis or 
indirect effects on a patient’s ability to recognize onset of hypoglycemia. Changes that affect 
glucose homeostasis include direct increase in insulin secretion from the pancreas, indirect 
increase in insulin secretion through decreased degradation of incretin hormones (GLP-1 
and GIP), cytotoxic effects on pancreatic cells leading to increase insulin release, decrease in 
gluconeogenesis, increase in glucose utilization and storage, decrease in glucagon release 
from the pancreatic ǂ cells, and decreased gastric emptying (Pandit et al, 1993). Many agents 
affect glucose homeostasis through a combination of these mechanisms. Location of 
mechanism is exhibited in table 8. 
 
Pancreas Liver Periphery Kidney Gut 
 Pentamidine 
 Fluoroquinolones
 Sulfamethoxazole
 Quinine 
 Indomethacin 
 Exenatide 
 Sulfonylureas 
 Non-sulfonylurea 
secretagogues 
 Sitagliptin 
 Ethanol 
 Indomethacin
 Exenatide 
Pramlintide 
 Sitagliptin 
 Beta 
adrenergic 
antagonists 
 Angiotensin 
converting 
enzyme 
(ACE) 
inhibitors 
 Indomethacin
 Insulin 
 Indomethacin  Pramlintide 
Table 8. Location of action of agents implicated in drug-induced hypoglycemia 
5.2 Specific agents 
Specific agents, including risk factors and frequency of hypoglycemic events, are discussed 
below. 
5.2.1 Fluoroquinolones 
Fluoroquinolones are antibiotics which exhibit their antimicrobial activity through 
inhibition of DNA gyrase and topoisomerase IV, enzymes involved in bacterial cell division 
(Product Information: Tequin, 2006). The class includes the following agents:  ciprofloxacin, 
gatifloxacin, levofloxacin, moxifloxacin, norfloxacin, ofloxacin, and rofloxacin. Though there 
are reports of hypoglycemia with most agents in this class, a majority of the evidence with 
fluoroquinolone-induced hypoglycemia is with gatifloxacin (Murad et al, 2009). The exact 
mechanism of this hypoglycemic effect is not clear; however, it is proposed that 
fluoroquinolones increase insulin secretion from the pancreas and may have a 
pharmacokinetic or pharmacodynamic interaction with various antidiabetic agents, 
including sulfonylureas. The adverse effect does not appear dose-related and presents 
typically within the first three days of therapy for less severe hypoglycemia (Frothingham, 
2005; Gajjar, et al, 2000; Park-Wyllie et al, 2006; Product Information: Tequin, 2006). More 
severe episodes, specifically those requiring hospitalization or prolonged hospitalization, 
are more common after three days of therapy. Hypoglycemia has been reported with 
intravenous and oral therapies in both outpatient and inpatient settings, and 
discontinuation of the medication is often required to resolve the glucose abnormalities 
(Murad et al, 2009). Though new onset diabetes has been reported, risk factors for patients 
who are more likely to experience hypoglycemic episodes are: pre-existing diabetes, 
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concomitant use of hypoglycemic medications, advanced age, and decreased renal function 
(Frothingham, 2005; Product Information: Tequin, 2006; Yip & Lee, 2006). 
5.2.2 Indomethacin 
Indomethacin belongs to the class of agents called non-steroidal anti-inflammatory drugs 
(NSAIDs). Anti-inflammatory agents, including salicylates, are all thought to increase risk of 
hypoglycemia, with indomethacin having the greatest evidence, likely due to the population 
being treated. Though often used for osteoarthritis and other inflammatory conditions, 
indomethacin may also be used to close a patent ductus arteriosis in neonates, often  in 
those born prematurely. Increases in pancreatic insulin secretion, decreases in insulin 
clearance, increases in glucose utilization in the periphery, and decreases in gluconeogenesis 
all appear to contribute to the hypoglycemic effects of these drugs. Less than three per cent 
of neonates exposed to therapeutic levels of intravenous indomethacin for patent ductus 
arteriosis experience hypoglycemia (Product Information: Indocin, 2010). Whether this effect 
is dose-related is unclear; however, the risk may be significantly decreased by use of a 
concomitant infusion of intravenous glucose (Hosono, 1999). 
5.2.3 Pentamidine 
Pentamidine is an anti-fungal agent which exhibits its effects through inhibition of microbial 
nuclear metabolism. Direct cytotoxic effects on beta cells of the pancreas results in increased 
secretion of insulin. This early release of insulin is due to the lytic effects on the cell which 
result in cell death. This can ultimately result in insulin-dependent diabetes as a result of 
this cell loss (Pandit et al, 1993). Pentamidine is associated with a 6-40% risk of 
hypoglycemia in patients receiving intravenous or intramuscular administration. 
Hypoglycemia is most commonly seen in patients with acquired immune deficiency 
syndrome (AIDS) treated for Pneumocystis carinii (Murad et al, 2009 & Product Information: 
Pentin, 2008) (Product Information: Pentam, 2008 & Product Information: Nebupent, 2008). 
The risk of hypoglycemia and resultant pancreatic damage associated with pentamidine is 
greater with higher doses, higher cumulative doses, and prolonged use (Pandit et al, 1993). 
There also appears to be increased risk with use of pentamidine mesylate compared to 
pentamidine isothionate (Waskin, 1996). 
5.2.4 Quinine 
Quinine is an anti-malarial agent used acutely for systemic and cerebral disease. More 
than 300 cases of hypoglycemia have been reported with quinine therapy and 30 clinical 
studies have demonstrated similar findings (Murad et al, 2009). The crux of the 
hypoglycemic effects of quinine appear to be the result of increased insulin secretion from 
beta cells. Though this is most common in patients infected with malaria, there are reports 
of quinine-induced hypoglycemia in patients without malaria. Patients with malaria often 
exhibit more severe or sustained hypoglycemia since the organism responsible for 
malaria, Plasmodium falciparum, independently lowers glucose levels. There is also an 
increased risk of hypoglycemia with higher doses of quinine and with infusion times of 
intravenous doses of less than one hour. Manufacturers recommend intravenous infusions 
occur over four hours to minimize risk of hypoglycemia (Product Information: Qualaquin, 
2010). Quinine-induced hypoglycemia can be resistant to traditional therapy with glucose 
and glucagon; however, treatment with octreotide has been shown to be beneficial (Pandit 
et al, 1993). 
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5.2.5 Beta blockers 
Non-selective beta-adrenergic antagonists, also known as beta blockers, are vasodilators 
which are often used to treat hypertension and cardiac disease. A list of non-selective beta 
blockers is provided in table 9 below. These agents have been linked with hypoglycemic 
effects in patients with and without diabetes (Murad et al, 2009). Oral formulations are most 
commonly the culprit; however, hypoglycemia associated with topical formulations is 
documented (Pandit et al, 1993). Though there are numerous reports of hypoglycemia 
associated with beta blockers , the quality of the data is limited. Murad, et al, theorizes that 
the high numbers of reports are a representation of the frequency of use of these agents 
more than the frequency of the actual hypoglycemic events (Murad et al, 2009).  
There are two proposed mechanisms for this hypoglycemic effect in beta blockers. First, 
there is a blunting of the signs and symptoms of hypoglycemia (White, 2007). The exception 
to this blunting effect is sweating, an important educational point for all patients (Product 
Information:  Innopran XL, 2010). The second mechanism is a direct potentiation of the 
effects of insulin. This heightened insulin effect increases glucose utilization in the periphery 
and inhibits lipolysis. Further, there is a diminished physiologic response to hypoglycemia 
in patient receiving beta blockers, specifically a decrease in glycogenolysis and 
gluconeogenesis (Pandit et al, 1993 & White, 2007). Patients at greatest risk for 
hypoglycemia with beta blockers include patients with hepatic disease, patients on 
hemodialysis, neonates, and patients with type 1 diabetes (Product Information:  Innopran 
XL, 2010). Use of selective beta blockers, such as atenolol, metoprolol, and bisoprolol are 
thought to have a decreased risk of hypoglycaemia and may be a reasonable alternative to 
patients unable to tolerate non-selective agents (Pandit et al, 1993). 
  
Non-selective beta-adrenergic antagonists 
Alprenolol 
Bucindolol 
Carteolol 
Nadolol 
Penbutolol 
Pindolol 
Propranolol 
Sotalol 
Timolol 
Non-selective beta-adrenergic antagonists with 
additional alpha antagonism:
Carvedilol 
Labetalol
Table 9. Non-selective beta-adrenergic antagonists (beta blockers) 
5.2.6 ACE inhibitors 
Angiotensin converting enzyme (ACE) inhibitors are a class of drugs that are typically used 
for hypertension and cardiovascular disease. Eleven studies document the potential for 
ACEI inhibitor-associated hypoglycemia, and a majority of these are with the use of 
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captopril (Murad et al, 2009; Herings et al, 1995). All members of this class are listed in table 
10 below. Though the mechanism for this drug-induced hypoglycaemia is not well defined, 
it is proposed that the increase in bradykinins associated with ACE inhibitor use may cause 
an increase in insulin sensitivity (Pandit et al, 1993; Vuorinen-Markkola & Yki-Jarvinen, 
1995). One study by Pollare, et al, suggests that captopril increases glucose utilization in the 
periphery compared to use of hydrochlorothiazide (Pollare et al, 1989); however, Wiggam, 
et al, demonstrates in one study that ACE inhibitors have no impact on hepatic or peripheral 
insulin sensitivity (Wiggam et al, 1998). Because of the contradicting information available, 
the actual impact of ACE inhibitors on blood glucose is not clear. ACE inhibitor therapy is a 
mainstay of hypertension, diabetes, and cardiovascular disease management. To date, there 
is insufficient evidence available to warrant discontinuation of this therapy in patients at 
risk for hypoglycemia with these disease states; however, in patients with suspected 
captopril-induced hypoglycemia, switching to another ACE inhibitor is a reasonable 
recommendation. 
 
ACE Inhibitors 
Benazepril 
Captopril 
Enalapril 
Fosinopril 
Lisinopril 
Moexipril 
Perindopril 
Quinapril 
Ramipril 
Trandolapril 
Table 10. Angiotensin Converting Enzyme (ACE) Inhibitors 
5.2.7 Ethanol 
Despite the poor level of evidence, ethanol has been touted as one of the most common 
causes of drug-induced hypoglycaemia in the United States (Pandit et al, 1993). The 
proposed mechanism is a direct suppression of gluconeogenesis in the liver, a process that 
typically occurs in more long-standing fasting states. Some studies suggest that this 
hypoglycemic potential is present in both occasional and chronic alcohol consumers and is 
more common with use of non-carbohydrate laden drinks (Pandit et al, 1993). Because of 
this, patients at greater risk for hypoglycemia should avoid consuming alcohol. 
6. Prevention  
One easy way to prevent drug-induced hypoglycemia is to avoid the medication that poses the 
potential for drug-induced hypoglycemia in patients that are at high risk for drug-induced 
hypoglycemia. Unfortunately, it may not be practical to avoid certain medications that may 
cause drug-induced hypoglycemia. As when deciding to use any medication, weigh the 
benefit of using the medication versus risk, in this case drug-induced hypoglycemia.  
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If avoiding the agent is not possible, attempt to minimize the risk of hypoglycemia by 
keeping in mind the following restrictions. Use extended-release/sustained-released 
products if that is an option for the medication needed (Pandit et al, 1993). Reinforce with 
patients the need to avoid alcohol intake (Pandit et al, 1993). Minimizing the lenth of time 
and dose of an offending agent may also be beneficial. Since hypoglycemia awareness is 
largely reliant on patient perception of the signs and symptoms of hypoglycemia, education 
is key (Cryer et al, 2003). Therefore, it is important to review the signs and symptoms of 
hypoglycemia with patients and caregivers. One way to monitor patients for evidence of 
hypoglycemia is to monitor their blood glucose concentrations, which is especially in 
important in patients with pre-existing diabetes. Blood glucose should be carefully 
monitored with initiation, dose changes, or discontinuation of any medication in patients 
with diabetes. It is usually recommended for patients to regularly check their fasting blood 
glucose readings during the initiation of a medication that can cause drug-induced 
hypoglycemia. The healthcare provider can make patient specific recommendations on how 
often to monitor blood glucose based on the patient’s underlying risk for hypoglycemia (e.g. 
patients already taking 1 or more agents that can cause drug-induced hypoglycemia or those 
patients with a diagnosis of diabetes) as well as any manufacturer recommendations. In 
addition to instructing the patient to monitor and record their blood glucose levels at home, 
it is helpful for a healthcare provider to review the history of the patient’s blood glucose 
levels at every visit and ask about signs and symptoms of hypoglycemia. Tracking the 
patient’s weight and reviewing the trend over the time the patient is taking a potentially 
offending agent may also provide insight into whether the patient is experiencing 
asymptomatic hypoglycemia, especially when reviewed with the patient’s fasting blood 
glucose levels. When at all possible, patients should not be taking multiple agents that may 
cause drug-induced hypoglycemia. Healthcare providers should also be diligent to review a 
patient’s medication profile for drug interactions, pharmacokinetics and pharmacodynamic, 
with potentially offending hypoglycemic agents. Tables 11 and 12 provide a summary of 
points to remember when prescribing medications with a potential for drug-induced 
hypoglycemia.  
 
Prescribing Considerations 
Use extended or sustained release products when possible 
Avoid alcohol intake 
Minimize the length of time on an offending agent 
Utilize the lowest effective dose of the offending agent 
Avoid having multiple medications in the patient’s profile that can cause hypoglycemia 
Screen the patient,s medication profile for drug interactions – pharmacokinetic and 
pharmacodynamic 
 
Table 11. Specific Prescribing Considerations When Prescribing Medications with a Potential 
to Cause Drug-Induced Hypoglycemia 
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Prescriber Considerations Patient Education Points 
Monitor blood glucose levels at clinic visits Demonstration of self-monitoring of 
blood glucose 
Discussion of timing of blood glucose 
monitoring and target levels 
Inquire about experiences with hypoglycemia, 
including specific signs/symptoms 
Monitor for signs/symptoms of 
hypoglycemia 
Review appropriate treatment of 
hypoglycemia 
Weigh the patient at clinic visits and review the 
trend 
 
Table 12. Monitoring Points When Patients Are Taking Medications with a Potential to 
Cause Drug-Induced Hypoglycemia 
7. Management 
When measures to prevent drug-induced hypoglycemia do not work or when appropriate 
prevention measures were not able to be undertaken, hypoglycemia, especially symptomatic 
hypoglycemia, must be treated. Specific, evidence-based recommendations for management 
of drug-induced hypoglycemia are not readily available. In the absence of guidelines for 
drug-induced hypoglycemia, patients who experience this should be treated according to 
readily accepted guidelines for managing hypoglycemia in patients with diabetes (Cryer et 
al, 2009, American Diabetes Association, 2011). 
7.1 Signs and symptoms of hypoglycemia 
As described in the section “Defining Hypoglycemia,” patients may experience a variety of 
nonspecific symptoms (neurogenic symptoms and neuroglycopenic symptoms) as well as 
physical signs than can be attributed to hypoglycemia. Since there are not clear distinctions 
in hypoglycemic symptoms that occur regardless of the source of the symptom – drug-
induced, diabetes mellitus, or  another disease state, it is important that patients and 
caregivers be knowledgeable of the signs and symptoms of hypoglycemia. Sometimes 
friends and family members are the ones that recognize the patient is experiencing 
symptoms that can be attributed to hypoglycemia (Cryer et al, 2003). In particular they may 
notice changes in the patient’s behavior, mood, speech, or train of thought as the patient is 
trying to communicate with them.       
7.2 Differential diagnosis 
When hypoglycemia is suspected it is important to recognize that the signs and symptoms a 
patient may complain of or present with are nonspecific and often other causes of the signs 
and symptoms must be ruled out. In 2009 the Endocrine Society released a clinical practice 
guideline specifying a workup strategy for patients who experience hypoglycemia in the 
absence of DM (Cryer, et al, 2009). The guidelines instruct the healthcare provider to review 
the patient’s past medical history, physical exam, review of systems, laboratory data, and 
medications – current and past. These guidelines detail additional workup to undertake if 
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the cause of hypoglycemia is not apparent (Cryer, et al, 2009). However, the guidelines are 
very specific in stating that patients should be confirmed to have Whipple’s triad- 
documented by signs and/or symptoms of hypoglycemia along with a low blood glucose 
concentration and recovery of the patient/resolution of the hypoglycemic signs/symptoms 
when the patient’s blood glucose is raised – before the additional workup is pursued (Cryer, 
et al, 2009).        
7.3 Treatment of hypoglycemia 
While it is important to determine the cause of a patient’s hypoglycemia, once signs and 
symptoms of hypoglycemia are recognized it is imperative to quickly treat the patient’s 
hypoglycemia. Since there are no guidelines that are specific to managing drug-induced 
hypoglycemia, the current recommendations for managing hypoglycemia in patients with 
DM should be followed. Regardless of the cause of hypoglycemia, patients that are 
conscious should be given 15 – 20 g of glucose or any carbohydrate that contains glucose 
(American Diabetes Association, 2011). See Table 13 for specific examples of 15 – 20 g 
carbohydrate sources (National Diabetes Information Clearinghouse, 2008). The patient’s 
blood glucose should be monitored in 15 minutes and they should continue to receive 15 – 
20 g of glucose until their blood glucose level is greater than 70 mg/dl (3.9 mmol/l). Once 
the patient’s blood glucose is above 70 mg/dl (3.9 mmol/l), the patient should eat 
something more substantial (a meal or snack) to maintain their blood glucose in a normal 
range, usually 70 -130 mg/dl (3.9 – 7.2 mmol/l) (American Diabetes Association, 2011).  
 
Product 1 serving = 15 g carbohydrates 
Glucose Products 3 – 4 tablets 
1 serving of glucose gel 
Beverages 4 oz. = ½ cup of fruit juice 
4 oz = ½ cup of non-diet soft drink 
8 oz = 1 cup of milk 
Hard Candy 5 – 6 pieces 
Sugar or honey 1 tablespoon 
Adapted from National Diabetes Information Clearinghouse, 2008. 
Table 13. Quick Sources of Glucose  
Hypoglycemia is defined as severe when a patient cannot treat their hypoglycemia on their 
own due to loss of consciousness. In cases of severe hypoglycemia, caregivers should 
administer glucagon (American Diabetes Association, 2011). It should be noted that 
glucagon is a prescription medication, available as a glucagon kit, whereas the glucose 
products routinely used for mild to moderate hypoglycemia are available without a 
prescription. Caregivers should be trained on glucagon administration since it requires 
preparation of the dose and intramuscular administration (Lilly, 2005). It is also important 
for patient and caregivers to routinely check the expiration date on the glucagon kit to 
ensure it is still in date (American Diabetes Association, 2011). Although there are numbers 
indicating the occurrence of hypoglycemia, it is unclear how often drug-induced 
hypoglycemia is severe. Therefore, it will be up to the healthcare provider to determine the 
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patient’s risk for severe hypoglycemia. If a patient is taking multiple agents that can alter 
their blood glucose or if they have multiple risk factors for hypoglycemia then it would be 
reasonable for the patient to be provided with a prescription for a glucagon kit and for their 
caregiver(s) to receive appropriate training. If the patient’s hypoglycemia is severe enough 
to warrant attention of emergency personnel, then additional measures to raise their blood 
glucose may include the administration of intravenous dextrose sources.           
In addition to quickly trying to reverse the patient’s hypoglycemia once it has occurred, a 
plan should be developed to prevent future episodes of hypoglycemia. As discussed in the 
“Prevention” section in Table 12, prescribing of the medication suspected to be causing 
hypoglycemia should be continued under close supervision. Providers should recognize 
that if offending drugs must be continued that there may need to be decreases in the dose, 
duration, or timing of administration.   Once an episode of hypoglycemia has occurred, 
afterwards is an appropriate time to re-visit how the situation was managed and to make 
sure there is an action plan for any future episodes. A summary of general principles of the 
management of drug-induced hypoglycemic episodes are found below in Table 14.  
 
Initial Treatment of Hypoglycemia 
Recognition of signs and symptoms of hypoglycemia – differentiation between mild – 
moderate versus severe 
Appropriate treatment of hypoglycemia – patient-treated with a quick acting glucose 
source versus caregiver assisted with glucagon or healthcare provider treatment with 
dextrose 
Plan for Prevention of Future Episodes of Hypoglycemia 
Evaluation of offending medication for adjustment in dosage and length of therapy 
Consider of timing of administration of medication with meals  
Consistent intake of meals/snacks 
Institute blood glucose monitoring 
Table 14. General Management of Drug-Induced Hypoglycemia 
7.4 Resolution of hypoglycemia 
Once a patient has experienced a hypoglycemic episode, the patient and healthcare 
providers will be anxious for it be resolved. Since the mechanism by which each offending 
medication causes hypoglycemia is different, the time to resolution of hypoglycaemia will 
vary accounting for both pharmacokinetic and pharmacodynamic properties of the 
offending medication as well as any other interfering medications. The mechanism by which 
hypoglycemia occurs will also determine whether the effects are reversible. In the case of 
pentamidine, the beta cell loss that may occur is not reversible (Pandit et al, 1993).   
8. Discussion 
When evaluating drug-induced hypoglycemia in comparison to what is reported in the 
literature, it is important to remember that the cases reported in the literature could be a 
result of publication bias. Many of the cases denoted patients with hospitalization and 
morbidity indicating patients were experiencing severe hypoglycemia (Murad et al, 2009). 
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Mild cases of hypoglycemia, even potentially asymptomatic cases, have not necessarily been 
documented in the literature, reinforcing the under-reporting of drug-induced 
hypoglycemia (Murad et al, 2009). In the most recent systematic review conducted, the 
reviewers noted that cases in the literature were patients who were taking medications at 
their recommended doses; however, the patients still experienced severe, symptomatic 
hypoglycemic episodes (Murad et al, 2009). This systematic review did reinforce the risk 
factors for drug-induced hypoglycemia that had been reported in earlier literature. Cases 
identified for the review were often patients of advanced age and who were experiencing 
renal and/or hepatic insufficiency. However, one additional patient risk factor that was 
identified was severe systemic disease (Murad et al, 2009). The drugs most often implicated 
in the reported cases were anti-diabetic agents, specifically insulin and sulfonylureas, as 
denoted in Table 6 (Murad et al, 2009). 
9. Conclusion 
Hypoglycemia is a potentially common and underreported complication of medication use 
which can result in significant morbidity and mortality. Patients must be educated on 
common signs and symptoms of hypoglycemia, especially when specific symptoms may be 
masked by medications. Specific characteristics, including renal insufficiency, hepatic 
insufficiency, and advancing age, may predispose patients to development of drug-induced 
hypoglycemia. Patient evaluation may help the clinician identify patients at greatest risk 
and avoid complications associated with the more commonly associated drugs. Preventative 
strategies include drug avoidance, minimizing time or dose of offending agents, using 
controlled-release formulations where available, limiting use of the medication or multiple 
medications which may cause hypoglycemia, and frequent, proactive blood glucose 
monitoring. Though these strategies may not prevent all occurrences, they may limit the 
number or severity of those that do happen. In the case of a hypoglyemic episode, 
management strategies should include those used in managing hypoglycemia of non-drug-
induced origin.  
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